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Novarti’s Kymriah and Kite’s Yescarta, are the first Chimeric Antigen Receptor (CAR) T-cell therapies to receive 
regulatory approval both in the United States and in Europe. They are suggested as new face in cancer 
treatment and in particular in B-cell acute 
lymphoblastic leukaemia (ALL). Their promising results 
have encouraged numerous research groups and 
manufacturers to explore the potential of those 
therapies in the treatment of various cancer types, 
resulting into 317 clinical trials globally (based on a 
recent search on ClinicalTrials.gov (2018)). Today, in 
the UK CAR T cells are only available through clinical 
trial schemes (approximately 250 patients per trial), 
thus being produced and delivered at a small scale. 
However, their recent European Medicines Agency 
Approval will allow them to become available to a wider 
patient population (approximately 40,000 eligible 
patients by 2031 (Figure 1), based on research 
performed on the UK patient population), requiring, 
therefore significant scale up/out both in the 
manufacturing line as well as in the logistics/supply 
chain model. In this work we focus on the design of a 
modelling tool to assist the decision making in the 
design of the supply chain model of CAR T cell therapies. Expanding our previous work (Wang et al., 2018), we 
demonstrate the design of a Resource Technology Network (RTN) for the identification of the key 
steps/decisions in the CAR T supply chain model. Based on previous qualitative results (Papathanasiou, 2018), 
we present a comparison between three supply chain model structures and we introduce the concept of the 
“dynamic” supply chain model. The latter refers to a versatile supply chain network that is tailored to the varying 
therapy demand. Based on the demand profiles, the modelling tool decides on: (a) number and location of 
clinical sites, (b) number and location of manufacturing sites and (c) best means of transport for the therapy. 
Lastly, the model considers time restrictions related to product shelf life, as well as different business decisions 
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Figure 1 Forecast scenario of patient population 
eligible to receive CAR T cell therapies by 2031. 
Calculations are based on the assumption that only 
10% of the patients with B-cell malignancies in the UK 
will be able to receive the therapy. 
